- Home
- WVVI vs NERV Comparison
WVVI vs NERV Comparison
Compare WVVI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WVVI
- NERV
- Stock Information
- Founded
- WVVI 1983
- NERV 2007
- Country
- WVVI United States
- NERV United States
- Employees
- WVVI N/A
- NERV N/A
- Industry
- WVVI Beverages (Production/Distribution)
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- WVVI Consumer Staples
- NERV Health Care
- Exchange
- WVVI Nasdaq
- NERV Nasdaq
- Market Cap
- WVVI 13.0M
- NERV 14.6M
- IPO Year
- WVVI N/A
- NERV 2014
- Fundamental
- Price
- WVVI $2.55
- NERV $4.33
- Analyst Decision
- WVVI
- NERV Hold
- Analyst Count
- WVVI 0
- NERV 1
- Target Price
- WVVI N/A
- NERV $4.00
- AVG Volume (30 Days)
- WVVI 17.2K
- NERV 231.2K
- Earning Date
- WVVI 11-13-2025
- NERV 11-05-2025
- Dividend Yield
- WVVI N/A
- NERV N/A
- EPS Growth
- WVVI N/A
- NERV N/A
- EPS
- WVVI N/A
- NERV N/A
- Revenue
- WVVI $37,366,837.00
- NERV N/A
- Revenue This Year
- WVVI N/A
- NERV N/A
- Revenue Next Year
- WVVI N/A
- NERV N/A
- P/E Ratio
- WVVI N/A
- NERV N/A
- Revenue Growth
- WVVI N/A
- NERV N/A
- 52 Week Low
- WVVI $2.49
- NERV $1.15
- 52 Week High
- WVVI $7.18
- NERV $12.46
- Technical
- Relative Strength Index (RSI)
- WVVI 28.58
- NERV 58.79
- Support Level
- WVVI $2.50
- NERV $3.75
- Resistance Level
- WVVI $2.90
- NERV $4.60
- Average True Range (ATR)
- WVVI 0.28
- NERV 0.36
- MACD
- WVVI -0.02
- NERV -0.02
- Stochastic Oscillator
- WVVI 1.93
- NERV 74.55
About WVVI Willamette Valley Vineyards Inc.
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.